University of California, Los Angeles AIDS Prevention Treatment CTU

Site Details

LOCATION

9911 W. Pico Blvd.

Suite 980

Los Angeles, CA. 90035

Get Directions

Site Type

CTU

Site Trials

HIV Cure

Open and enrolling

A5386: N-803 with or without bNAbs for HIV-1 control in participants living with HIV-1 on suppressive ART

Scientists are looking for ways to effectively clear HIV that rests in areas of the body where standard antiretroviral treatment (ART) is unable to reach. IL-15 superagonist (N-803) appears to reactivate HIV that is “asleep” and is also thought to increase the body’s natural immune response to HIV. Broadly neutralizing antibodies (bNAbs), such as 10-1074 and VRC07-523LS, have been shown to control growth of HIV in the blood and to increase the body’s immune response to HIV. N-803 alone or in combination with bNAbs may provide greater control of HIV than previous efforts.

Mpox

Open and enrolling

A5418:Study of Tecovirimat for Human Monkeypox Virus (STOMP)

A5418 (STOMP) is a study of tecovirimat (also known as TPOXX) for the treatment of human monkeypox virus (HMPXV) disease.